Drugs that contain Selexipag

1. Uptravi patents expiration

UPTRAVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(3 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan
Aug, 2029

(5 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Jun, 2030

(6 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
Dec, 2036

(13 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Dec, 2036

(13 years from now)

Market Authorisation Date: 29 July, 2021

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...


How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage

UPTRAVI family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic